Spots Global Cancer Trial Database for pleural mesothelioma
Every month we try and update this database with for pleural mesothelioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Evaluation of Response by FLT PET in Mesothelioma | NCT06410625 | Pleural Mesothe... Treatment Respo... Chemotherapy Ef... | FLT PET imaging | 18 Years - | Ankara University | |
| Mesothelioma Early Detection by VOCs | NCT04106973 | Pleural Mesothe... Asbestos Exposu... Pleural Plaque | 18 Years - | Ascension South East Michigan | ||
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | NCT04334759 | Mesothelioma Pleural Mesothe... Malignant Pleur... | Durvalumab Standard Chemot... Ipilimumab and ... | 18 Years - | PrECOG, LLC. | |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | NCT04430842 | Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C... | QBS10072S | 18 Years - | Quadriga Biosciences, Inc. | |
| Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | NCT00037817 | Advanced Esopha... Primary Small C... Non-Small-Cell ... Pleural Mesothe... Cancers of Non-... | Decitabine Depsipeptide Celecoxib | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | NCT02585362 | Lung Cancer Gastro-Intestin... Breast Cancer Prostate Cancer Pleural Mesothe... Urothelial Carc... Renal Cell Carc... Ovarian Cancer | physical exerci... nutrition couns... whey protein su... | 18 Years - | Kantonsspital Winterthur KSW | |
| Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma | NCT00165555 | Pleural Mesothe... Malignant Pleur... | Cisplatin Sodium Thiosulf... | 18 Years - | Dana-Farber Cancer Institute | |
| TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study | NCT05538806 | Pleural Mesothe... | TTFields | 18 Years - | NovoCure Ltd. | |
| SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | NCT01445392 | Mesothelioma | Multicycle SS1P Pemetrexed Cisplatin Single cycle SS... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | NCT05337735 | Microsatellite ... Peritoneal Meso... Extrapulmonary ... Neuroendocrine ... Cervical Carcin... Hodgkin's Lymph... Pleural Mesothe... Small Cell Lung... | XmAb20717 | 18 Years - | M.D. Anderson Cancer Center | |
| International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | NCT03210298 | Peritoneum Canc... Peritoneum Neop... Pleural Cancer Pleural Effusio... Pleural Mesothe... Ovarian Cancer Gastric Cancer Appendix Cancer Pseudomyxoma Pe... Colorectal Canc... Pancreas Cancer Gallbladder Can... Ascites CUP Chemotherapeuti... | PIPAC | 10 Years - | University of Magdeburg | |
| International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | NCT03210298 | Peritoneum Canc... Peritoneum Neop... Pleural Cancer Pleural Effusio... Pleural Mesothe... Ovarian Cancer Gastric Cancer Appendix Cancer Pseudomyxoma Pe... Colorectal Canc... Pancreas Cancer Gallbladder Can... Ascites CUP Chemotherapeuti... | PIPAC | 10 Years - | University of Magdeburg | |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | NCT06097728 | Unresectable Pl... | Volrustomig Pemetrexed Carboplatin Cisplatin Nivolumab Ipilimumab | 18 Years - | AstraZeneca | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | NCT06097728 | Unresectable Pl... | Volrustomig Pemetrexed Carboplatin Cisplatin Nivolumab Ipilimumab | 18 Years - | AstraZeneca | |
| Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer | NCT00281125 | Non-Small Cell ... | PTK787 and Peme... | 18 Years - | Nevada Cancer Institute | |
| A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia | NCT05077111 | Pleural Effusio... Pleural Mesothe... Pleural Empyema Pulmonary Disea... Pleural Neoplas... Pulmonary Atele... Pleural Disease... Pericardial Eff... Mediastinal Lym... Pneumothorax an... Hemothorax Pyopneumothorax | Thoracic Epidur... General Anesthe... | 21 Years - 65 Years | Ain Shams University | |
| eRAPID: Online Symptom Reporting in Lung Cancer | NCT04324437 | Thoracic Cancer Non-small Cell ... Small-cell Lung... Pleural Mesothe... | eRAPID online s... | 18 Years - | University of Leeds | |
| Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma | NCT02899195 | Mesothelioma Pleural Mesothe... | Durvalumab | 18 Years - | PrECOG, LLC. | |
| Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma | NCT00996385 | Mesothelioma | Velcade (bortez... | 18 Years - | Columbia University | |
| Gene Therapy for Pleural Malignancies | NCT00299962 | Pleural Mesothe... Metastatic Pleu... | Adenoviral-medi... SCH 721015 | 18 Years - | University of Pennsylvania | |
| TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients | NCT02414945 | Pleural Mesothe... | Cyclophosphamid... Fludarabine Autologous tumo... Interleukin-2 | 18 Years - | University Health Network, Toronto | |
| A Study of SGN-CD228A in Advanced Solid Tumors | NCT04042480 | Cutaneous Melan... Pleural Mesothe... HER2 Negative B... Non-small Cell ... Colorectal Canc... Pancreatic Duct... | SGN-CD228A | 18 Years - | Seagen Inc. | |
| A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma | NCT01279967 | Malignant Pleur... | ADI-PEG 20 | 18 Years - | Barts & The London NHS Trust | |
| SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | NCT01445392 | Mesothelioma | Multicycle SS1P Pemetrexed Cisplatin Single cycle SS... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | NCT04040231 | Mesothelioma Pleural Mesothe... Wilms Tumor | Galinpepimut-S Nivolumab Sargramostim | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | NCT01160458 | Pleural Mesothe... Peritoneal Meso... | IMC-A12 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | NCT06362369 | Advanced Cancer Advanced Solid ... Melanoma Metastasis Pleural Mesothe... Renal Cell Carc... MSI-High Mismatch Repair... Colorectal Canc... Hepatocellular ... Hepatocellular ... Renal Cell Canc... Kidney Cancer Skin Cancer Non Small Cell ... NSCLC Anaplastic Lymp... ALK Genomic Tum... | Alintegimod Ipilimumab Nivolumab | 18 Years - | 7 Hills Pharma, LLC | |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | NCT04914897 | Pleural Mesothe... Non-small Cell ... | THOR-707 Pembrolizumab | 18 Years - | Sanofi | |
| Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | NCT00535951 | Carcinoma, Non-... Mesothelioma | LBH589 | 18 Years - | Novartis | |
| A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | NCT02707666 | Pleural Mesothe... | Pembrolizumab Cisplatin and P... | 18 Years - | University of Chicago | |
| Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma | NCT04823741 | Mesothelioma, M... Gene Abnormalit... Pleural Mesothe... | PLEURAL BIOCOLL... | 18 Years - 95 Years | Hospices Civils de Lyon | |
| TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study | NCT05538806 | Pleural Mesothe... | TTFields | 18 Years - | NovoCure Ltd. | |
| Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma | NCT02899195 | Mesothelioma Pleural Mesothe... | Durvalumab | 18 Years - | PrECOG, LLC. | |
| TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO | NCT05628376 | Lung Cancer, No... Small Cell Lung... Pleural Mesothe... | 18 Years - | University College, London | ||
| Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | NCT06416930 | Pleural Mesothe... | Cadonilimab Com... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer | NCT00281125 | Non-Small Cell ... | PTK787 and Peme... | 18 Years - | Nevada Cancer Institute | |
| Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma | NCT04823741 | Mesothelioma, M... Gene Abnormalit... Pleural Mesothe... | PLEURAL BIOCOLL... | 18 Years - 95 Years | Hospices Civils de Lyon | |
| Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | NCT05930665 | Pleural Mesothe... | Cadonilimab+Bev... | 18 Years - | Sun Yat-sen University | |
| A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | NCT02707666 | Pleural Mesothe... | Pembrolizumab Cisplatin and P... | 18 Years - | University of Chicago | |
| A Study of SGN-CD228A in Advanced Solid Tumors | NCT04042480 | Cutaneous Melan... Pleural Mesothe... HER2 Negative B... Non-small Cell ... Colorectal Canc... Pancreatic Duct... | SGN-CD228A | 18 Years - | Seagen Inc. | |
| Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | NCT00094978 | Carcinoma, Smal... Carcinoma, Non-... Esophageal Neop... Mesothelioma | Depsipeptide Flavopiridol (a... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy | NCT01160458 | Pleural Mesothe... Peritoneal Meso... | IMC-A12 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma | NCT00402766 | Mesothelioma | Cisplatin Imatinib Mesyla... Pemetrexed Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma | NCT00165555 | Pleural Mesothe... Malignant Pleur... | Cisplatin Sodium Thiosulf... | 18 Years - | Dana-Farber Cancer Institute | |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | NCT05714553 | Advanced Cancer Advanced Solid ... Neoplasm Malign... Metastatic Canc... Melanoma Classical Hodgk... Non Small Cell ... Renal Cell Carc... Urothelial Carc... Head and Neck S... Subungual Squam... Oesophageal Car... MSI-H Colorecta... Gastric Cancer Triple Negative... Endometrial Car... Pleural Mesothe... | Fosifloxuridine... Leucovorin Pembrolizumab Docetaxel | 18 Years - | NuCana plc | |
| Evaluation of Response by FLT PET in Mesothelioma | NCT06410625 | Pleural Mesothe... Treatment Respo... Chemotherapy Ef... | FLT PET imaging | 18 Years - | Ankara University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
